NPPB and cardiovascular disorder: Interestingly, the investigated miRNAs augmented the clinical biomarker NT-proBNP’s efficacy and improved its capacity to differentiate between groups with comorbid cardiovascular disease risk more effectively than NT-proBNP alone.